CLRB - Cellectar Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.69
+0.43 (+6.87%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.26
Open6.87
Bid6.39 x 100
Ask6.70 x 400
Day's Range6.40 - 7.25
52 Week Range5.70 - 20.60
Volume298,391
Avg. Volume111,322
Market Cap11.847M
Beta0.90
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.00
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / U.S. stocks closed up on Tuesday, as the Federal Reserve announced that it would be flexible in the face of changing conditions and will not move too quickly ...

  • GlobeNewswire3 days ago

    Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

    Cellectar Biosciences (CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces positive interim results from the company’s Phase 2 clinical trial for its lead product candidate CLR 131, in patients with diffuse large B-cell lymphoma (DLBCL). After a single 25.0 mCi/m2 IV administration of CLR 131, patients with relapsed/refractory DLBCL were assessed for response. “We are very encouraged by the strong response rates and meaningful reductions in tumor volumes seen in the trial to date in this very sick and heavily pretreated relapsed/refractory DLBCL patient population,” stated James Caruso, president and chief executive officer of Cellectar Biosciences.

  • MarketWatch4 days ago

    Cellectar Biosciences shares surge 15% on results of one cancer patient in mid-stage trial

    Cellectar Biosciences Inc. (CLRB) shares rose 15% in Tuesday trade after the company announced that one patient in a phase 2 trial for its cancer therapy had a major improvement in the amount of tumor material in her body, or an about 94% reduction. The trial, which is studying the therapy in patients with certain B-cell malignancies, intends to enroll about 80 participants total, according to Clinicaltrials.gov, and has an expected completion date of March 2019. The patient, who has a rare type of cancer called Waldenstrom macroglobulinemia, was administered two doses of the therapy, CLR 131, after which she showed the large reduction in tumor burden and complete resolution of four of five targeted tumor masses, the company said.

  • Benzinga4 days ago

    Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug

    Cellectar Biosciences Inc (NASDAQ: CLRB ) shares are pushing northward on over five times their average volume after the company reported positive results from an ongoing midstage trial. Cellectar shares ...

  • GlobeNewswire4 days ago

    Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study

    Cellectar Biosciences (CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that a patient in the lymphoplasmacytic lymphoma (LPL) arm with advanced Waldenstrom macroglobulinemia, enrolled in the CLR 131 Phase 2 trial, showed a 94% reduction in tumor burden and complete resolution in four of five targeted tumor masses. As part of Cellectar’s Phase 2 study in hematologic cancers, the patient received a single 25mCi/m2 dose of CLR 131 over a 30-minute infusion period. Based on this initial response and additional clinical factors, the treating physician, Sikander Ailawadhi, M.D., Associate Professor, Division of Hematology/Oncology, Department of Medicine, The Mayo Clinic, Jacksonville, Florida, administered a second dose of CLR 131 on day 123.

  • GlobeNewswire8 days ago

    Cellectar Announces 1-for-10 Reverse Stock Split

    Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces a 1-for-10 reverse split of its common stock, effective at the close of business today. Stockholders approved the reverse stock split at Cellectar’s special meeting of stockholders held on July 12, 2018. On July 9, 2018, Cellectar’s Board of Directors approved the implementation of the reverse stock split and determined the appropriate reverse stock split to be a ratio of 1-for-10, subject to stockholder approval.

  • GlobeNewswire12 days ago

    Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

    Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of Ewing’s sarcoma, a rare pediatric cancer.

  • GlobeNewswire23 days ago

    Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

    The response rate of the DLBCL cohort exceeded pre-specified criteria. This group represents the second of four cohorts to be expanded in this Phase 2 study. “Relapse or refractory DLBCL is an aggressive cancer and the initial response rates from the cohort leave us optimistic in CLR 131’s potential to have a positive impact on patients with life-threatening hematologic cancers.

  • GlobeNewswirelast month

    Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131

    MADISON, Wis., June 07, 2018-- Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces ...

  • GlobeNewswirelast month

    FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma

    Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer. “There is a critical need for new therapies in the fight against deadly diseases such as rhabdomyosarcoma and we continue to increase our focus on delivering innovative solutions to patients suffering from such rare cancers,” said John Friend, M.D., chief medical officer of Cellectar.

  • GlobeNewswire2 months ago

    Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

    Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported recent corporate highlights and financial results for the three months ended March 31, 2018. Received orphan drug designation and rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for CLR 131 to treat neuroblastoma. Received orphan drug designation from the FDA for CLR 131 to treat rhabdomyosarcoma, a rare pediatric cancer.

  • GlobeNewswire2 months ago

    Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

    Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of rhabdomyosarcoma, a rare pediatric cancer.

  • ACCESSWIRE3 months ago

    Blog Exposure - Cellectar Receives Rare Pediatric Disease Designation from FDA

    LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Cellectar Biosciences, Inc. (NASDAQ: CLRB) ("Cellectar") all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLRB as the Company's latest news hit the wire. On May 02, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (RPDD) to its lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. Active-Investors.com is currently working on the research report for Seattle Genetics, Inc. (NASDAQ: SGEN), which also belongs to the Healthcare sector as the Company Cellectar Biosciences.

  • GlobeNewswire3 months ago

    Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma

    Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation (RPDD) to the company’s lead phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma. “Neuroblastoma is a devastating cancer most often found in infants and young children.

  • ACCESSWIRE4 months ago

    Cellectar BioSciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Cellectar BioSciences, Inc. (NASDAQ: CLRB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 22, 2018 at 8:30 AM Eastern ...

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! CSRA Inc (NYSE: CSRA ) stock gained nearly 1.5 percent ...